HBE

#### PATENT COOPERATION TREATY

Express Mail Label No: EQ 311373240 US

From the INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY				Attorney Docket No.: 101171-1P US			
INTERNATIONAL PRELIMINARY EX	CODE	DATE		- V	DOT.		
To: GLOBAL INTELLECTUAL PROP AstraZeneca AB SE-151 85 Södertälje SUEDE	ANKOM 3  DATA ENTERED FINAL CHECK	1 JAN			PCT -2 FEE 2006  TIFICATION OF TRANSMITTAL OF EINTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY  (PCT Rule 71.1)		
	CHECK		T	of mailin nonth/yea	07.04.0000		
Applicant's or agent's file reference 101171-1 WO		_ <del></del>			IMPORTANT NOTIFICATION		
International application No. PCT/GB2004/003464	International fili 12.08.2004	nternational filing date (da)			Priority date (day/month/year) 15.08.2003		
Applicant ASTRAZENECA AB							

- The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary report on patentability and its annexes, if any, established on the international application.
- A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
- Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

#### 4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary report on patentability. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

The applicant's attention is drawn to Article 33(5), which provides that the criteria of novelty, inventive step and industrial applicability described in Article 33(2) to (4) merely serve the purposes of international preliminary examination and that "any Contracting State may apply additional or different criteria for the purposes of deciding whether, in that State, the claimed inventions is patentable or not" (see also Article 27(5)). Such additional criteria may relate, for example, to exemptions from patentability, requirements for enabling disclosure, clarity and support for the claims.

Name and mailing address of the international preliminary examining authority:



European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465 **Authorized Officer** 

Hebert, W

Tel. +49 89 2399-2152



PATENT COOPERATION TREATY

### **PCT**

CODE	DATE	NTD

**GIPS** 

### INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

ANKOM 3 1 JAN 2005

(PCT Article 36 and Rule 70)

DATA

		(1 0 1 7 11 11 10 10 10 1		ENTERED	
				FINAL	
Applicant's or agent's fit 101171-1 WO	e reterence	FOR FURTHER A	CTION	See CHECK	
100	, , , , <del>-</del>	1		Osinsib John (Jan. 6 - 4) (1 - 4)	
		International filing date	(day/month/year)	Priority date (day/month/year)	
PCT/GB2004/003464 12.08.2004				15.08.2003	
International Patent Classification (IPC) or national classification and IPC C07D487/14, A61K31/5025, A61P31/04					
Applicant ASTRAZENECA A	В				
This report is the Authority under	e international pr Article 35 and tra	reliminary examination re ansmitted to the applicar	port, established by that according to Article	nis International Preliminary Examining 36.	
2. This REPORT	consists of a total	of 6 sheets, including t	nis cover sheet.		
		by ANNEXES, comprising			
a. 🗆 sent to t	he applicant and	to the International Bure	au) a total of sheets,		
☐ she	The second secon				
☐ shed					
b. (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s)), containing a sequence listing and/or tables related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).					
4. This report con	ains indications i	relating to the following it	ems:		
⊠ Box No. I	Basis of the or				
☐ Box No. II	Priority				
☑ Box No. III	•	ment of opinion with rega	rd to novelty, inventive	e step and industrial applicability	
☐ Box No. IV	Lack of unity o		•		
⊠ Box No. V	Reasoned stat		2) with regard to novel supporting such state	ty, inventive step or industrial ment	
☐ Box No. VI	Certain docum				
☐ Box No. VII	Certain defects	s in the international app	lication		
		ations on the internation			
Date of submission of the	e demand		Date of completion of t	his report	
08.06.2005			27.01.2006		
Name and mailing address preliminary examining a	uthority:	nal	Authorized Officer	John Marien, S.	
European Patent Office D-80298 Munich			Grassi, D	t <b>a)))</b>	
Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465		Telephone No. +49 89	2399-		

. .

10/567797

# IAP20 Rec'd PCT/PTO 0 9 FEB 2006

# INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/GB2004/003464

	Box	( No. I Basis of the report			
1.	With	n regard to the <b>language</b> , this report is based on the international application in the language in which it was d, unless otherwise indicated under this item.			
		This report is based on translations from the original language into the following language , which is the language of a translation furnished for the purposes of:			
		<ul> <li>☐ international search (under Rules 12.3 and 23.1(b))</li> <li>☐ publication of the international application (under Rule 12.4)</li> <li>☐ international preliminary examination (under Rules 55.2 and/or 55.3)</li> </ul>			
2.	2. With regard to the elements* of the international application, this report is based on (replacement sheets whi have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report):				
	Des	cription, Pages			
	1-53	as originally filed			
Claims, Numbers					
	1-23	as originally filed			
		a sequence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing			
3.		The amendments have resulted in the cancellation of:			
		☐ the description, pages ☐ the claims, Nos.			
		☐ the drawings, sheets/figs			
		☐ the sequence listing (specify): ☐ any table(s) related to sequence listing (specify):			
4.	□ had Sup	This report has been established as if (some of) the amendments annexed to this report and listed below not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the optemental Box (Rule 70.2(c)).			
		☐ the description, pages ☐ the claims, Nos. ☐ the drawings, sheets/figs			
		☐ the sequence listing (specify): ☐ any table(s) related to sequence listing (specify):			
	4	If item 4 applies some or all of these sheets may be marked "superseded."			

# INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/GB2004/003464

	Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability					
1.	The obv	The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:				
		the entire international application,				
	×	claims Nos. 20-22				
		because:				
	⊠	the said international application, or the said claims Nos. (with respect to industrial applicability) relate to the following subject matter which does not require an international preliminary examination (specify):				
		see separate sheet				
		the description, claims or drawings (indicate particular elements below) or said claims Nos. are so unclear that no meaningful opinion could be formed (specify):				
		the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.				
		no international search report has been established for the said claims Nos.				
		the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrative Instructions in that:				
		the written form		has not been furnished		
				does not comply with the standard		
		the computer readable form		has not been furnished		
				does not comply with the standard		
		the tables related to the nucleo not comply with the technical re	tide : equir	and/or amino acid sequence listing, if in computer readable form only, do ements provided for in Annex C-bis of the Administrative Instructions.		
		See separate sheet for further	detai	ils		

# INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/GB2004/003464

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes: Claims

1-23

No: Claims

Inventive step (IS)

Yes: Claims
No: Claims

1-23

Industrial applicability (IA)

Yes: Claims

1-19,23

No: Claims

2. Citations and explanations (Rule 70.7):

see separate sheet

10/567797

## IAPZOROS DETATIO 09 FEB 2006

#### INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (SEPARATE SHEET)

International application No.

PCT/GB2004/003464

Reference is made to the following documents:

D1: WO 03/002567 A (2003-01-09)

D2: GHORAB, MOUSTAFA M.: "Synthesis and radiation stability of some new biologically active pyrazolo[3,4-d]pyrimidines" ACTA PHARMACEUTICA (ZAGREB), 50(2), 93-110

#### Re Item III

Claims 20-22 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(i) PCT).

#### Re Item V

- 1) The subject-matter of present claims 1-23 is new (Article 33(2) PCT).
- 2) The subject-matter of claims 1-23 involves an inventive step (Article 33(3) PCT).

The closest prior art is represented by D1 relating to inhibitors of Murl for the treatment of *H. pylori* infections.

The present compounds differ from the compounds of D1 in that they comprise an additional condensed heteroring.

The technical problem underlying the present application is seen in the provision of alternative compounds for the treatment of *H. pylori* infections.

D2 relates to antibacterial compounds exhibiting the present basic ring system but different substituents (cf. compounds III in scheme 1). However, the combination of D1 with D2 would not prompt the skilled in the art to the compounds according to present claims 1 or 10, therefore, inventive activity appears to be present.

The claims 2-9 and 11-18 designate preferred embodiments and are therefore

### , ' INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (SEPARATE SHEET)

International application No.

PCT/GB2004/003464

also inventive.

The claims 19-23 relate to the preparation or the use of the inventive compounds and are therefore also fulfilling the said requirement.